Nalmefene in Alcohol Dependence and Borderline Personality Disorder
NCT ID: NCT02752503
Last Updated: 2016-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SHame prOpensity in bOrderline Personality Disorder
NCT03994510
Assessment of Sense of Identity in Patients Diagnosed With Borderline Personality Disorder. A Pilot Study
NCT04948905
Delving Into Borderline Personality Disorder Clinical Trial Experiences
NCT05989529
Treating Alcohol Use In Older Adults With Depression
NCT00018824
Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD
NCT02134223
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nalmafene
Nalmefene
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nalmefene
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Borderline personality disorder according to DSM 5
* CGI-BPD \> 3
* Female have to use contraception
Exclusion Criteria
* Severe organic disorder
* Pregnancy or breastfeeding
* Allergy to Nalmefene
* Subjects with Opioids use disorder or in treatment with opioid agonists
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Universitari General de Catalunya
OTHER
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan C Pascual, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIBSP-NAL-2014-76
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.